AiTan (rivoceranib)

This result was superior to the second-line treatment with nab-paclitaxel, which resulted in a PFS of 8 months and best overall response of stable disease with slight shrinkage. The present case indicates that a combination of utidelone with apatinib/anlotinib exhibited antitumor activity in a patient with HR+/HER2- mBC with BMs. Therefore, this combination offers a promising therapeutic option for the clinical treatment of patients with breast cancer and BMs.

The combined application of ERK inhibitors, U0126 or trametinib, with the VEGFR inhibitor Apatinib, additively suppresses angiogenesis and tumor growth of HCC1806 in nude mice. These findings provide new therapeutic strategies for TNBC.

This case highlights the potential antitumor activity of apatinib in breast cancer patients with presenting with PLC. While further studies are necessary, this therapeutic approach could represent a viable option for managing breast cancer in the context of a visceral crisis. The case also emphasizes the importance of individualized treatment strategies and further research to substantiate these promising findings.

P2, N=0, Withdrawn, M.D. Anderson Cancer Center | N=16 --> 0 | Trial completion date: Nov 2028 --> Nov 2024 | Initiation date: Apr 2025 --> Nov 2024 | Not yet recruiting --> Withdrawn | Trial primary completion date: Nov 2026 --> Nov 2024

P4, N=128, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University

P2, N=31, Not yet recruiting, The First Hospital of China Medical University; The First Hospital of China Medical University

P2, N=33, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

P3, N=885, Completed, Jiangsu HengRui Medicine Co., Ltd. | Active, not recruiting --> Completed

The most frequent grade 3 or 4 treatment-related adverse event was neutropenia (n = 4, 29%). The combination of camrelizumab, gemcitabine, and apatinib showed promising efficacy and acceptable safety in patients with advanced PD-L1-positive biliary tract cancer.

Despite the unfavorable prognosis associated with advanced GC, the implementation of personalized treatment approaches may still prove beneficial for select patients. In patients with HER2-positive GC with extensive metastatic involvement, the use of the HER2-targeted combination with apatinib has demonstrated the potential to prolong both PFS and overall survival.

This was mirrored by a reduction in the IC50 values for cisplatin and apatinib to 0.8257 µM and 10.79 µM, respectively. The E2F8-TPX2 axis promotes glycolysis and angiogenesis in LC cells, which in turn accelerates cancer progression and reduces chemosensitivity. The online version contains supplementary material available at 10.1007/s10616-024-00655-w.

Finally, phase II clinical trials involving HER2-altered NSCLC patients demonstrated promising treatment outcomes with trastuzumab deruxtecan, trastuzumab emtansine, pyrotinib, pyrotinib + apatinib and trastuzumab + pertuzumab + docetaxel. In conclusion, the prevalence of HER2 alteration among Malaysian NSCLC patients falls within the global range. A systematic review of clinical trials revealed promising treatment outcomes and Malaysian NSCLC patients with HER2 alterations are anticipated to similarly benefit from HER2-targeted therapies.

P2, N=44, Recruiting, Beijing Sanbo Brain Hospital | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Aug 2024 --> Aug 2025

EGCG regulated glycolysis levels in NSCLC through VEGF overexpression, and enhanced the antitumor effect of apatinib in NSCLC through VEGF-regulated glycolysis. Taken together, EGCG strengthened the protective effects of apatinib in NSCLC through glycolysis mediated by VEGF.

Immunohistochemistry showed that combining apatinib with chloroquine could reduce the expression of CD31 and Ki67 and increase the expression of caspase-3. Apatinib inhibits proliferation and induces apoptosis in H1975 and H1446 lung cancer cells with high VEGFR2 expression and autophagy in H1975 and H446 cells.

P2, N=46, Not yet recruiting, Beijing Tsinghua Chang Gung Hospital

P=N/A, N=97, Active, not recruiting, First Hospital of China Medical University

P2, N=16, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Sep 2024 --> Apr 2025

P2, N=620, Recruiting, Fudan University | N=140 --> 620

Apatinib combined with vinorelbine is effective and safe in patients with locally advanced or metastatic refractory HER2-negative breast cancer. The findings of this study con-tribute to a better understanding of the metabolic effect of apatinib and vinorelbine therapy.

P2, N=43, Not yet recruiting, Fujian Cancer Hospital

P2, N=30, Recruiting, Ruijin Hospital | Trial completion date: May 2024 --> Sep 2027 | Trial primary completion date: Feb 2024 --> Oct 2026

P2, N=29, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

P1/2, N=29, Recruiting, Fujian Cancer Hospital | Not yet recruiting --> Recruiting | N=20 --> 29 | Trial completion date: Dec 2023 --> Jun 2025 | Trial primary completion date: Oct 2023 --> Dec 2024

P=N/A, N=38, Not yet recruiting, Zhujiang Hospital of Southern Medical University; Zhujiang Hospital of Southern Medical University

P4, N=114, Not yet recruiting, Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital

P4, N=41, Not yet recruiting, Affiliated Hospital of North Sichuan Medical College; Affiliated Hospital of North Sichuan Medical College

P4, N=80, Not yet recruiting, Shandong University Affiliated Provincial Third Hospital; Shandong University Affiliated Provincial Third Hospital

P2, N=30, Not yet recruiting, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital); The First Affiliated Hospital of Nanjing Medical U

P2, N=63, Not yet recruiting, China-Japan Friendship Hospital; China-Japan Friendship Hospital

P2, N=147, Recruiting, The First Affiliated Hospital of Zhengzhou University | Trial completion date: Dec 2024 --> Dec 2025

In addition, this combined treatment significantly reduced the expression of NG2 and HIF1α in mouse tumor tissues, indicating a more normalized vascular density, and also increased the proportion of CD8+ T cells. Low-dose apatinib enhances the antitumor effect of PD-1 inhibitor by normalizing tumor-related blood vessels, alleviating intratumor hypoxia and altering immunosuppressive microenvironment (IM).

Patients with HCC that have a high TIGIT expression on their T cells exhibited poorer baseline characteristics, immunosuppressive status, and prognosis after receiving TACE combined with apatinib and camrelizumab and maybe more suited to receive TACE combined with apatinib treatment instead.

P2, N=128, Recruiting, Sun Yat-sen University | Unknown status --> Recruiting | Trial completion date: May 2020 --> May 2027 | Trial primary completion date: May 2019 --> May 2025

These findings indicated that apatinib and antigen-specific DC-T combination therapy was more efficient in oncolysis by regulating pro-/anti-angiogenic inducers and improving the immune state in the OS microenvironment. This study proved that it was feasible to employ immunotherapy with therapeutic agents in OS treatment, which may provide a new approach in addition to the combination of surgery with chemotherapy in tumour treatment.

Synergistically, ATO and APA have a more significant impact on inhibiting cell proliferation than each drug independently. ATO and APA may be mediating its action through the stabilization of GRB10 thus acting as a tumor suppressor. We thus, preliminarily report the impact of GRB10 stability as a target for SCLC treatment.

P2, N=35, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University

Camrelizumab plus apatinib showed promising antitumor activity with manageable toxicity in patients with advanced or recurrent endometrial cancer who had failed at least one prior systemic therapy. The findings of this study support further investigation of camrelizumab plus apatinib as an alternative therapeutic option, especially for patients with MSS/pMMR tumors.

P2, N=38, Not yet recruiting, Zhujiang Hospital

P2/3, N=294, Active, not recruiting, Shanghai Zhongshan Hospital | Recruiting --> Active, not recruiting | Phase classification: PN/A --> P2/3 | Trial primary completion date: Mar 2024 --> Jul 2025

P2, N=716, Recruiting, Fudan University | Phase classification: P1/2 --> P2

P2, N=80, Not yet recruiting, Fujian Cancer Hospital